Topics:

Tykerb Gets Priority FDA Review

Tykerb Gets Priority FDA Review

LONDON, United Kingdom—GlaxoSmithKline's New Drug Application for Tykerb (lapatinib), an oral small molecule dual inhibitor of EGFR and HER2, has been granted priority review by the FDA. The designation requires that the agency decide on a drug application no longer than 6 months after submission, which was September 18, 2006, for Tykerb. The Tykerb application is for treatment of advanced or metastatic HER2-positive breast cancer in combination with capecitabine (Xeloda) for patients who have received prior treatment.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.